References
- Mauri M, Ramacciotti D. Menopause and personal bodily changes. Minerva Ginecol 2005;57:Suppl 1:1–9.
- Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987;257:2176–2180.
- Gambacciani M, Pepe A. Vasomotor symptoms and cardiovascular risk. Climacteric 2009;12 Suppl 1:32–35.
- Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 2003;289:537–538.
- Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186–2191.
- Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16–22.
- Messina M. Insights gained from 20 years of soy research. J Nutr 2010;140:2289S–2295S.
- Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999;129:758S–767S.
- Messina M. Investigating the optimal soy protein and isoflavone intakes for women: a perspective. Womens Health (Lond Engl) 2008;4:337–356.
- Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344–1351.
- Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007;57:26–30.
- Whitcroft S, Herriot A. Insulin resistance and management of the menopause: a clinical hypothesis in practice. Menopause Int 2011;17:24–28.
- Dayspring TD, Pokrywka G. Impact of triglycerides on lipid and lipoprotein biology in women. Gend Med 2010;7:189–205.
- Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol 2009;4: 553–563.
- Jun Yin Zhanguo, Gao, Dong Liu Zhijun, Liu, and Jianping, Ye Berberine improves glucose metabolism through induction of glycolysis Am J Physiol Endocrinol Metab 2008;294: E148–E156.
- Colacurci N, Chiantera A, de Novellis V, Fornaro F, Manzella D, Arciello A et al. Soy isoflavones and endothelial function in healthy postmenopausal women. Menopause. 2005; 12 (3): 299–307.
- Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68:1375S–1379S.
- Kleijn de MJJ, Schouw van der YT, Wilson PWF, Grobbee DE, Jacques PF. Dietary intake of phytoestrogenes is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: the Framingham Study. J Nutr 2002;132: 276–282.
- Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 1998;12:605–623.
- Palacios S, Rojo IA, Cancelo MJ, Neyro JL, Castelo-Branco C. Women’s perception of the efficacy of a soy extract with probiotic: the M3 study. Gynecol Endocrinol 2008;24:178–183.
- Caputi AP, Arcoraci V, Benvenuti C, Estronet Study group. Soy isoflavones, lactobacilli, vitamin D3 and calcium. Observational study in menopause. Gior It Ost Gin 2006; XXVIII, n. 3: 212–221.
- Mucci M, Carraro C, Mancino P, Monti M, Papadia LS, Volpini G, Benvenuti C. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause. Minerva Ginecol 2006;58:323–334.
- Agosta C, Atlante M, Benvenuti C, Estronet Study Group. Randomized Controlled Study on Clinical Efficacy of isoflavones plus Lactobacilli, Associated or not with a Natural Anxiolytic Agent in Menopause. Minerva Ginecol. 2011: 63, 1–7.
- Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008;7:17.